Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T21:17:43.840Z.
Calculation as of: 2026-10-06T21:17:43.840Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9cbfdb9b702203632c67f1d3ce56f9042d1c779579fe07ac28526a5c99bc9a0a
PE RATIO
N/A
Market Cap
$426.51M
PE Ratio
N/A
TTM Avg
193.87
3Y Avg
193.87
5Y Avg
193.87
Market Cap
$439.55M
PE Ratio
40.33
TTM Avg
54.06
3Y Avg
54.06
5Y Avg
54.06
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NeuroPace, Inc. (NPCE) | $431.97M | N/A | N/A | N/A | N/A |
| YD Bio Limited Ordinary Shares (YDES)vs › | $435.61M | N/A | N/A | N/A | N/A |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $426.51M | N/A | 193.87 | 193.87 | 193.87 |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $438.07M | N/A | N/A | N/A | N/A |
| Assembly Biosciences, Inc. (ASMB)vs › | $439.55M | 40.33 | 54.06 | 54.06 | 54.06 |
| NeoGenomics, Inc. (NEO)vs › | $424.10M | N/A | 138.05 | 184.03 | 168.06 |
| Tectonic Therapeutic, Inc. (TECX)vs › | $422.86M | N/A | N/A | N/A | N/A |
| Tilray Brands, Inc. (TLRY)vs › | $422.72M | N/A | N/A | N/A | N/A |
| Ovid Therapeutics Inc. (OVID)vs › | $442.34M | N/A | 2.09 | 2.09 | 2.09 |
| Prothena Corporation plc (PRTA)vs › | $419.87M | N/A | 33.09 | 33.09 | 33.09 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$12.67
Forward EPS (Est.)
$-0.58
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
